Korro Bio (NASDAQ:KRRO) vs. Alseres Pharmaceuticals (OTCMKTS:ALSE) Head to Head Analysis

Alseres Pharmaceuticals (OTCMKTS:ALSE) and Korro Bio (NASDAQ:KRRO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.

Institutional & Insider Ownership

13.2% of Korro Bio shares are held by institutional investors. 8.9% of Alseres Pharmaceuticals shares are held by insiders. Comparatively, 4.6% of Korro Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Alseres Pharmaceuticals and Korro Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alseres Pharmaceuticals	0	0	0	0	0.00
Korro Bio	1	8	1	0	2.00

Korro Bio has a consensus target price of $76.00, suggesting a potential upside of 806.38%. Given Korro Bio’s stronger consensus rating and higher possible upside, analysts clearly believe Korro Bio is more favorable than Alseres Pharmaceuticals.

Profitability

This table compares Alseres Pharmaceuticals and Korro Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alseres Pharmaceuticals	N/A	N/A	N/A
Korro Bio	-1,199.53%	-68.87%	-45.91%

Earnings and Valuation

This table compares Alseres Pharmaceuticals and Korro Bio”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alseres Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Korro Bio	$2.27 million	34.80	-$83.58 million	($9.41)	-0.89

Alseres Pharmaceuticals has higher earnings, but lower revenue than Korro Bio.

Summary

Korro Bio beats Alseres Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Alseres Pharmaceuticals

Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson’s disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.

About Korro Bio

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.